Urogenital Neoplasms: Clinical Trials

7491 completed, 2626 recruiting, 2246 unknown, 1688 terminated. 5455 Phase 2, 3813 Not applicable, 3251 Phase 1, 1514 Phase 3, 274 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	5455	Completed 2477, Terminated 812, Recruiting 748, Unknown 540, Active not recruiting 418, Not yet recruiting 219, Withdrawn 219, Suspended 15, Enrolling by invitation 7
Not applicable	3813	Completed 1613, Recruiting 691, Unknown 625, Active not recruiting 260, Terminated 223, Not yet recruiting 208, Withdrawn 137, Enrolling by invitation 40, Suspended 16
Phase 1	3251	Completed 1523, Terminated 510, Recruiting 500, Active not recruiting 260, Unknown 228, Withdrawn 124, Not yet recruiting 78, Suspended 22, Enrolling by invitation 6
Phase 3	1514	Completed 676, Recruiting 224, Unknown 179, Active not recruiting 176, Terminated 149, Not yet recruiting 55, Withdrawn 48, Suspended 4, Enrolling by invitation 3
Phase 4	274	Completed 134, Unknown 45, Recruiting 34, Terminated 26, Not yet recruiting 18, Active not recruiting 8, Withdrawn 6, Suspended 2, Enrolling by invitation 1
Early Phase 1	253	Completed 104, Unknown 37, Recruiting 28, Terminated 26, Active not recruiting 23, Withdrawn 16, Not yet recruiting 15, Enrolling by invitation 2, Suspended 2

Follow Urogenital Neoplasms: new trials by email Literature Review of Urogenital Neoplasms trials Research Report on Urogenital Neoplasms

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Evaluation of Naloxegol in the Prevention of POI After Cystectomy Naloxégol oxalate, Placebo oral tablet - Bladder Cancer, Cystostomy; Complications	Phase 2	Withdrawn	Institut Paoli-Calmettes		2032-01-01	2026-10-14
PROstate Cancer Risk Calculator for ACTionable Clinical Decision-making in Nigeria (a) Training and (b) Supported risk assessment - Prostate Cancer, Risk Assessment	Not applicable	Not yet recruiting	Ahmadu Bello University	89	2029-03-01	2026-07-29
Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder Cancer AI Uro-Cam - Bladder Cancer	Not applicable	Not yet recruiting	Chinese University of Hong Kong	60	2028-07-01	2026-10-28
Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors Exercise and dietary recommendations - Ovarian Cancer	Not applicable	Not yet recruiting	Oncare Madrid	32	2028-05-01	2026-10-08
A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy 177Lu-PSMA-I&T - escalating renal absorbed dose, 177Lu-PSMA-I&T - recommended phase 2 regime - Cancer, Prostate Cancer	Phase 1 / Phase 2	Not yet recruiting	CHU de Quebec-Universite Laval	500	2028-03-01	2025-03-30
REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants REGN21353, Nezastomig, Sarilumab Prophylaxis (Contingency) - Metastatic Castration-Resistant Prostate Cancer, mCRPC	Phase 1 / Phase 2	Not yet recruiting	Regeneron Pharmaceuticals	192	2027-06-28	2026-09-30
Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial Balstilimab, Biospecimen Collection, Botensilimab - Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8	Phase 2	Recruiting	National Cancer Institute (NCI)	16	2027-05-17	2026-10-21
Development of Systems and Education for Cervical Cancer Prevention (DOSE-CC) DOSE-CC Intervention: Educational Sessions - Cervical Cancer Screening, Cervical Cancer	Not applicable	Not yet recruiting	Boston Medical Center	80000	2027-05-01	2026-10-30
Topical Curcumin for HPV Related Cervical Disease Curcumin C3 Complex, Placebo - Neoplasm Cervix	Phase 2	Not yet recruiting	Lisa Flowers	200	2027-04-01	2026-05-08
PITCH - Impacting Hereditary Cancer Testing Genetic testing education video - Ovarian Cancer, Genetic Testing	Not applicable	Not yet recruiting	Rachel Miller	200	2027-04-01	2026-09-10
Cancer Awareness Among Syrian Migrants PMT-Based Cancer Screening Educational Intervention, PMT-Based Cancer Screening Education Program - Breast Cancer Screening, Cervical Cancer Screening	Not applicable	Not yet recruiting	Toros University	30	2027-03-09	2026-10-15
Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer (MIBC) This is a non-interventional, observational, prospective study. - NMIBC, MIBC		Not yet recruiting	Bladder Cancer Advocacy Network	1400	2027-03-01	2026-10-26
Understanding the Role of MyCareGorithm as a Visual Digital Platforms in Cancer Treatment Education and Patient Comprehension of Oncology Treatment Plans Survey - Head and Neck Cancer, Prostate Cancer	Not applicable	Not yet recruiting	M.D. Anderson Cancer Center	94	2027-03-01	2026-10-01
Hugo™ RAS Urology Post-Market Clinical Study Robotic Assisted Urologic Surgery - Prostatectomy, Cystectomy		Not yet recruiting	Medtronic - MITG	110	2027-02-23	2026-10-30
Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and Pain Biospecimen Collection, Low-Dose Aspirin, Patient Observation - Endometrial Carcinoma	Phase 4	Not yet recruiting	Mayo Clinic	20	2027-02-12	2026-08-05
Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma Biospecimen Collection, Bone Scan, Computed Tomography - Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8	Phase 3	Not yet recruiting	National Cancer Institute (NCI)	400	2027-02-10	2026-07-08
Prostate Stereotactic Radiation and Radio-induced Lymphocyte Apoptosis for Predicting Late Toxicities in Prostate Cancer (PROSTERA) Radio-induced Lymphocyte Apoptosis (RILA) Assay, Stereotactic body radiotherapy (SBRT) - Prostate Cancer	Not applicable	Not yet recruiting	Clinique Sainte Clotilde	220	2027-02-01	2026-10-26
SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma Stereotactic Body Radiation Therapy (SBRT), Anlotinib, Bemarituzumab - Locally Advanced or Metastatic Renal Cell Carcinoma	Phase 2	Not yet recruiting	Fujian Cancer Hospital	27	2027-02-01	2026-10-01
Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer losartan, Paclitaxel - Platinum Resistant Ovarian Cancer	Phase 2	Not yet recruiting	Massachusetts General Hospital	27	2027-02-01	2026-09-22
A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer NDV-01 (sustained-release gemcitabine-docetaxel) - Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)	Phase 3	Not yet recruiting	Relmada Therapeutics, Inc.	393	2027-02-01	2026-09-02

Showing 20 of 16784. Sign in to see all of them.

Narrower conditions

Prostatic Neoplasms (6448)  ·  Ovarian Neoplasms (3262)  ·  Uterine Cervical Neoplasms (2247)  ·  Carcinoma, Renal Cell (1958)  ·  Urinary Bladder Neoplasms (1726)  ·  Endometrial Neoplasms (1392)  ·  Breast Neoplasms (1263)  ·  Neoplasms (1092)  ·  Kidney Neoplasms (956)  ·  Fallopian Tube Neoplasms (828)  ·  Carcinoma, Ovarian Epithelial (785)  ·  Carcinoma, Non-Small-Cell Lung (696)  ·  Colorectal Neoplasms (665)  ·  Neoplasm Metastasis (632)  ·  Lung Neoplasms (585)

Broader conditions

Urogenital Diseases (16769)  ·  Neoplasms by Site (16705)  ·  Neoplasms (15692)  ·  Genital Diseases (13010)  ·  Male Urogenital Diseases (10911)  ·  Female Urogenital Diseases and Pregnancy Complications (10698)  ·  Female Urogenital Diseases (10697)  ·  Genital Diseases, Male (6839)  ·  Genital Neoplasms, Male (6800)  ·  Genital Diseases, Female (6607)  ·  Genital Neoplasms, Female (6550)  ·  Prostatic Diseases (6461)  ·  Neoplasms by Histologic Type (4533)  ·  Urologic Diseases (4414)

Interventions

Paclitaxel (618)  ·  Carboplatin (605)  ·  Cisplatin (475)  ·  Docetaxel (431)  ·  pembrolizumab (430)  ·  Gemcitabine (370)  ·  Bevacizumab (362)  ·  Radiotherapy (347)  ·  Magnetic Resonance Spectroscopy (318)  ·  Nivolumab (266)  ·  Prednisone (263)  ·  enzalutamide (221)  ·  Cyclophosphamide (204)  ·  Specimen Handling (195)  ·  Leuprolide (190)

Sponsors

National Cancer Institute (NCI) (665)  ·  M.D. Anderson Cancer Center (378)  ·  Memorial Sloan Kettering Cancer Center (329)  ·  University Health Network, Toronto (175)  ·  AstraZeneca (167)  ·  Pfizer (147)  ·  Gynecologic Oncology Group (145)  ·  Mayo Clinic (138)  ·  Dana-Farber Cancer Institute (126)  ·  Novartis Pharmaceuticals (116)  ·  Merck Sharp & Dohme LLC (115)  ·  Jonsson Comprehensive Cancer Center (99)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (95)  ·  GlaxoSmithKline (94)  ·  Duke University (92)

Countries

United States (8155)  ·  China (1722)  ·  Canada (1475)  ·  France (1321)  ·  United Kingdom (1144)  ·  Italy (1066)  ·  Spain (936)  ·  Germany (812)  ·  Netherlands (675)  ·  Australia (667)  ·  South Korea (652)  ·  Belgium (648)  ·  Denmark (430)  ·  Poland (412)  ·  Japan (410)

Top investigators

Lei Li, M.D. (38)

Results publications

PMID 37185961, PMID 37146227, PMID 37407274, PMID 41276263, PMID 34350976, PMID 31401903, PMID 35170751, PMID 27238653, PMID 28410911, PMID 24722180, PMID 33270906, PMID 41698328, PMID 25577718, PMID 33465252, PMID 33538338, PMID 36884035, PMID 36971688, PMID 38421243, PMID 38421252, PMID 39695768, PMID 40966692, PMID 19097774, PMID 19238149, PMID 22894553, PMID 25712310, PMID 25819287, PMID 27626136, PMID 29272162, PMID 30633128, PMID 32203306, PMID 32994091, PMID 33526329, PMID 37526095, PMID 38320143, PMID 39462179, PMID 16394300, PMID 20818904, PMID 22747660, PMID 23228299, PMID 23922302, PMID 25592642, PMID 26961146, PMID 27626365, PMID 29342393, PMID 30207593, PMID 30380365, PMID 32379297, PMID 32499241, PMID 32779730, PMID 33058158

NIH funding

2023 (132), U10CA027469 (95), U10CA180868 (80), 2017 (79), 2016 (69), 2025 (67), 2019 (61), P30CA033572 (59), 2018 (58), 2015 (47), P30CA016672 (45), P30CA043703 (44), 2008 (42), 2014 (42), 2009 (39)